Chemistry, manufacturing, and controls (CMC) development of NES-100 as a nasal spray of a new analgesic
Ended Awarded Last action
- Contract number
- 75N91025F00025
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,346,384
Award facts
- Contract value 100% obligated
- $1,346,384.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
This is a $1,346,384.00 cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute (NCI) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for the chemistry, manufacturing, and controls (CMC) development of NES-100 as a nasal spray of a new analgesic. The contract has a period of performance through June 25, 2026 and does not have a set-aside designation, indicating Leidos Biomedical Research Inc. competed on an unrestricted basis. As an FFRDC contractor for the NCI, Leidos Biomedical Research Inc. provides comprehensive biomedical research and facilities support services to federal agencies, with a focus on the National Institutes of Health (NIH). This contract award demonstrates the company's extensive capabilities in areas such as clinical trials management, manufacturing of therapeutics, and specialized laboratory testing and analysis.
Quick answers
Who was awarded contract 75N91025F00025?
75N91025F00025 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 15, 2025.
How much is contract 75N91025F00025 worth?
The government has obligated $1,346,384 on 75N91025F00025.
Is contract 75N91025F00025 an order under another contract?
Yes. 75N91025F00025 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91025F00025 competed?
The extent of competition for 75N91025F00025 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award